Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant mFOLFOX-HAIC in High-Risk Hepatocellular Carcinoma
NCT07337421Phase 2Recruiting
- Sponsor
- Subei People's Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, folinic acid, fluorouracil in hepatocellular carcinoma (HCC), sponsored by Subei People's Hospital. Started Sep 2025; status: recruiting.
02
Drugs
oxaliplatinfolinic acidfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07337421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07337421.